T-Therapeutics, a Cambridge, UK-based biotechnology company developing TCR therapeutics, raised $48M in Series A funding.
The round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) with participation from Sanofi Ventures and the University of Cambridge Venture Fund. Concurrent with the financing, Graziano Seghezzi (Sofinnova Partners), Nihal Sinha (F-Prime), Samuel Bjork (Digitalis) and Robert Tansley (CIC) will join the Company’s Board of Directors.
The company intends to use the funds to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.
Led by CEO Allan Bradley, T-Therapeutics is a T cell receptor (TCR) company spun off from the University of Cambridge. It was created to harness the power of T cell biology to create safe and effective treatments for many cancers and autoimmune diseases. The company combines expertise in mouse genome engineering, expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. It is developing ‘optimal’ TCR based therapeutics using the proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of antigen-specific human TCRs, which are directed at multiple target classes.
FinSMEs
16/11/2023